Reprint

Non-Alcoholic Fatty Liver Disease Research 2016

Edited by
August 2018
566 pages
  • ISBN978-3-03897-600-4 (Paperback)
  • ISBN978-3-03897-601-1 (PDF)

This book is a reprint of the Special Issue Non-Alcoholic Fatty Liver Disease Research 2016 that was published in

Summary
This new book entitled "Non-Alcoholic Fatty Liver Disease Research 2016" covers a selection of recent research topics and current review articles in the field of nonalcoholic fatty liver disease (NAFLD) that have been recently published in a monographic Special Issue of the International Journal of Molecular Sciences (IJMS) journal. <false,>NAFLD is an “umbrella” definition that encompasses a spectrum of histopathological liver changes ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with/without fibrosis, “cryptogenic” cirrhosis and hepatocellular carcinoma. <false,>NAFLD has become one of the most common forms of chronic liver disease worldwide and its prevalence is expected to continue rising. <false,>It is now becoming increasingly clear that the clinical and economic burden of NAFLD does not only affect the liver, but also affects the risk of developing cardiovascular disease, type 2 diabetes mellitus, colo-rectal neoplasms, chronic kidney disease and other extra-hepatic diseases that have a considerable impact on health-care expenditures. <false,>Against this background, further research is needed to better understand the natural history, and the molecular pathogenesis of NAFLD, as well as to elucidate the underlying mechanisms by which NAFLD contributes to the increased cardiometabolic risk, and to disclose novel and effective treatment strategies for this increasingly prevalent and burdensome disease.<false,>Some of the leading international researchers in this area expressed a willingness to contribute to this book providing an updated, state-of-the-art view on the aforementioned topics, and also suggesting novel research avenues for NAFLD.
Format
  • Paperback
License
© 2018 by the authors; CC BY-NC-ND license
Keywords
NAFLD; metabolic syndrome; cyclodextrin; electron microscopy; lysosomes; NAFLD; lifestyle; diet; exercise; vitamins; amino acids; prebiotics; polyunsaturated fatty acids; polyphenols; medicinal plants; NAFLD; NASH; morbidly obese; liver fibrosis; lysosomial acid lipase; non-alcoholic fatty liver disease; Wolman Disease; cholesterol ester storage disease; hypercholesterolemia; AMPK; DPP-4 inhibitor; lipogenesis; non-alcoholic fatty liver disease; NAFLD; SREBP1c; teneligliptin; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; pathology; nonalcoholic fatty liver disease; NAFLD; nonalcoholic steatohepatitis; management; psoriasis; lysosomal acid lipase; cholesteryl ester storage disease; non-alcoholic liver disease; non-alcoholic steatohepatitis; cirrhosis; epidemiology; cirrhosis; clinical implications; direct acting antivirals; fibrosis; insulin resistance; hepatocellular carcinoma; NASH; pathophysiology; NAFLD; metabolic syndrome; insulin resistance; PNPLA3; biomarkers; diagnosis; exosomes; extracellular vesicles; microvesicles; NAFLD; non-alcoholic steatohepatitis (NASH); steatosis; steatohepatitis; proteomics; NAFLD; mitochondrial dysfunction; telomere; telomerase; liver disease progression; nonalcoholic fatty liver disease; cirrhosis; hepatocellular carcinoma; NAFLD; gut microbiota; lifestyle; diet and exercise; endothelial dysfunction; non-alcoholic fatty liver disease; metabolic syndrome; cardiovascular disease and risk; arterial hypertension; nonalcoholic fatty liver disease; free fatty acids; insulin resistance; nonalcoholic fatty liver disease; microbiota; diet; obesity; dysbiota; probiotics; liver transplant; multifactorial disease; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; SUA; liver damage; fibrosis; NASH; serum markers; oxidative stress; insulin resistance; metabolic syndrome; non-alcoholic fatty liver disease; chronic kidney disease; non-alcoholic steatohepatitis; inflammation; review; non-alcoholic fatty liver disease; steatohepatitis; liver fibrosis; arterial stiffness; pulse wave velocity; PNPLA3; morbid obesity; non-alcoholic fatty liver disease; simple steatosis; fatty acid metabolism; non-alcoholic steatohepatitis; insulin resistance; liver fat; obesity; PNPLA3; TM6SF2; NAFLD; ferritin; iron; cardiovascular disease; metabolic syndrome; fatty liver; colorectal cancer; adipokines; gut microbiota; nonalcoholic fatty liver; non-alcoholic steatohepatitis; fibrosis; hepatocellular carcinoma; cirrhosis; non-cirrhotic; HCV-associated NAFLD; insulin resistance; liver fibrosis; HCC; metabolic syndrome; diabetes; atherosclerosis; nonalcoholic fatty liver disease; hedgehog pathway; wound-healing response; NAFLD; steatosis; obesity; children; adolescent; fatty liver; NEFA; glycerol; lipolysis; insulin; magnetic resonance spectroscopy; NAFLD; NAFLD diet; insulin sensitivity; NIOR; reduction of body mass; fat reduction; liver fat; nonalcoholic fatty liver disease; renal function; obesity; children; nonalcoholic steatohepatitis; chronic hepatitis C; liver function; hepatic hemodynamics; WFA+-M2BP; fibrosis; inflammation; chemokines; genetics; microbiota; pattern-recognition receptors; nuclear receptors; hepatic stellate cells; macrophages; fatty liver; insulin resistance; free fatty acids; cholesterol; adiponectin; leptin; insulin; glucagon; glucagon-like peptide 1; ghrelin; irisin; selenoprotein P; n/a